JP7389465B2 - Melanin production inhibitor, collagen production promoter and antioxidant - Google Patents

Melanin production inhibitor, collagen production promoter and antioxidant Download PDF

Info

Publication number
JP7389465B2
JP7389465B2 JP2019218943A JP2019218943A JP7389465B2 JP 7389465 B2 JP7389465 B2 JP 7389465B2 JP 2019218943 A JP2019218943 A JP 2019218943A JP 2019218943 A JP2019218943 A JP 2019218943A JP 7389465 B2 JP7389465 B2 JP 7389465B2
Authority
JP
Japan
Prior art keywords
extract
artemisia
mugwort
production
melanin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019218943A
Other languages
Japanese (ja)
Other versions
JP2021088519A (en
Inventor
紘介 深田
泰弘 福田
祐子 村上
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Menard Cosmetic Co Ltd
Original Assignee
Nippon Menard Cosmetic Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Menard Cosmetic Co Ltd filed Critical Nippon Menard Cosmetic Co Ltd
Priority to JP2019218943A priority Critical patent/JP7389465B2/en
Publication of JP2021088519A publication Critical patent/JP2021088519A/en
Application granted granted Critical
Publication of JP7389465B2 publication Critical patent/JP7389465B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Description

本発明は、メラニン生成抑制剤、コラーゲン産生促進剤、抗酸化剤及び食品組成物に関する。 The present invention relates to melanin production inhibitors, collagen production promoters, antioxidants, and food compositions.

一般にシミ、ソバカス、日焼け等に見られる皮膚の色素沈着は、ホルモンの異常や紫外線の刺激により、皮膚内に存在するメラニン色素生成細胞がメラニン色素を過剰に生成し、これが皮膚内に沈着することが原因と考えられている。このような色素沈着を防ぐ方法の一つに、メラニンの過剰な生成を抑制する方法が知られている。従来、色素沈着の治療にはハイドロキノンやアスコルビン酸(ビタミンC)等を外用する処置が行われてきた。 Skin pigmentation, which is generally seen as spots, freckles, sunburn, etc., is caused by hormonal abnormalities or stimulation by ultraviolet rays, causing melanin pigment-producing cells in the skin to produce excessive melanin pigment, which is deposited in the skin. is thought to be the cause. One known method for preventing such pigmentation is to suppress excessive production of melanin. Conventionally, pigmentation has been treated by externally applying hydroquinone, ascorbic acid (vitamin C), and the like.

コラーゲンは、哺乳動物組織の約1/3を占める主要な構造タンパク質であり、軟骨、骨、腱、及び皮膚等の、多くのマトリックス組織の必須な成分である。その為、加齢等によってコラーゲン産生が低下することにより、骨粗鬆症、関節炎、腱鞘炎等の原因になることが知られている。また、創傷の治癒過程において、コラーゲンの産生量が亢進し、創傷の治癒を促進することが知られている。よって、コラーゲンの産生促進は、皮膚の創傷治癒の促進や、骨粗鬆症、関節炎及び腱鞘炎等の改善等にも有効である。 Collagen is a major structural protein that accounts for approximately one-third of mammalian tissues and is an essential component of many matrix tissues such as cartilage, bone, tendon, and skin. Therefore, it is known that collagen production decreases due to aging, etc., which causes osteoporosis, arthritis, tendonitis, etc. Furthermore, it is known that collagen production increases during the wound healing process, promoting wound healing. Therefore, promoting collagen production is also effective in promoting skin wound healing and improving osteoporosis, arthritis, tendonitis, and the like.

皮膚は生体の最外層に位置し、紫外線等の影響により活性酸素が発生しやすい臓器であり、絶えずその酸素ストレスに曝されている。一方、皮膚細胞内には活性酸素消去酵素が存在しており、その能力を超える活性酸素が発生しないかぎり活性酸素の傷害から皮膚細胞を防衛している。ところが、皮膚細胞内の活性酸素消去酵素の活性は加齢と共に低下することが知られており、活性酸素による傷害がその防御反応を凌駕したとき、皮膚は酸化され、細胞機能が劣化して老化してゆくと考えられる。また、皮膚以外の臓器においても、その活性酸素消去能を越える活性酸素に曝されたとき、機能低下が起こり老化したり、ガンや心筋梗塞等様々な生活習慣病が発症したりすると考えられる。そこで、活性酸素による傷害からの防御を目的として活性酸素消去剤や抗酸化剤が検討され、SODやカタラーゼ等の活性酸素消去酵素、SOD様活性物質等の活性酸素消去剤や抗酸化剤を含有した食品、化粧品、医薬部外品及び医薬品等が開発されている(特許文献1)。 The skin is located in the outermost layer of the living body, and is an organ where active oxygen is likely to be generated due to the influence of ultraviolet rays, etc., and is constantly exposed to oxygen stress. On the other hand, active oxygen scavenging enzymes exist within skin cells and protect skin cells from damage caused by active oxygen unless active oxygen exceeding its capacity is generated. However, it is known that the activity of active oxygen scavenging enzymes in skin cells decreases with age, and when the damage caused by active oxygen exceeds the protective response, the skin becomes oxidized, cell function deteriorates, and aging occurs. It is thought that this will continue. Furthermore, when organs other than the skin are exposed to active oxygen that exceeds their ability to scavenge active oxygen, it is thought that functional decline occurs, leading to aging, and the development of various lifestyle-related diseases such as cancer and myocardial infarction. Therefore, active oxygen scavengers and antioxidants have been investigated for the purpose of protecting against damage caused by active oxygen, and contain active oxygen scavengers and antioxidants such as active oxygen scavenging enzymes such as SOD and catalase, and SOD-like active substances. Foods, cosmetics, quasi-drugs, pharmaceuticals, and the like have been developed (Patent Document 1).

ヨモギ属植物は、世界中いたるところに分布し、その種類は250に及ぶことが知られている。ヨモギ属植物の薬効としては、ヨモギ(Artemisia princeps)の発酵物の含水エタノール抽出物がI型コラーゲン産生促進作用を有すること(特許文献2)等が知られている。 Plants of the genus Artemisia are distributed all over the world, and there are 250 known types. As for the medicinal effects of plants belonging to the Artemisia genus, it is known that a hydrous ethanol extract of a fermented product of Artemisia princeps has a type I collagen production promoting effect (Patent Document 2).

特開2015-212233号公報JP2015-212233A 特開2009-242263号公報JP2009-242263A

メラニン生成抑制効果、コラーゲン産生促進効果及び抗酸化効果に優れた素材が望まれているが、未だ十分満足し得るものが提供されていないのが現状である。 Although materials with excellent melanin production inhibiting effects, collagen production promoting effects, and antioxidative effects have been desired, at present no material that is fully satisfactory has been provided.

本発明者らは、上記課題を解決すべく鋭意検討した結果、オオヨモギ(Artemisia montana)の抽出物が優れたメラニン生成抑制作用、コラーゲン産生促進作用及び抗酸化作用を有することを見出し、本発明を完成するに至った。 As a result of intensive studies aimed at solving the above problems, the present inventors discovered that an extract of Artemisia montana has excellent melanin production inhibiting action, collagen production promoting action, and antioxidant action, and has developed the present invention. It was completed.

即ち、本発明は以下の発明を包含する。
(1)オオヨモギ(Artemisia montana)の抽出物を含有することを特徴とするメラニン生成抑制剤。
(2)オオヨモギ(Artemisia montana)の抽出物を含有することを特徴とするコラーゲン産生促進剤。
(3)オオヨモギ(Artemisia montana)の抽出物を含有することを特徴とする抗酸化剤。
(4)オオヨモギ(Artemisia montana)の抽出物を含有することを特徴とする、メラニンによる色素沈着、骨粗鬆症、関節炎、腱鞘炎、創傷、酸化ストレスに起因する疾病及び皮膚老化の改善及び予防用食品組成物。
That is, the present invention includes the following inventions.
(1) A melanin production inhibitor characterized by containing an extract of Artemisia montana.
(2) A collagen production promoter characterized by containing an extract of Artemisia montana.
(3) An antioxidant characterized by containing an extract of Artemisia montana.
(4) A food composition for improving and preventing diseases caused by melanin pigmentation, osteoporosis, arthritis, tenosynovitis, wounds, oxidative stress, and skin aging, characterized by containing an extract of Artemisia montana. .

本発明のメラニン生成抑制剤は色素沈着の治療、改善及び予防に、コラーゲン産生促進剤は、骨粗鬆症、関節炎、腱鞘炎及び創傷の治療、改善及び予防に、抗酸化剤は、酸化ストレスに起因する疾病及び皮膚老化の治療、改善及び予防に、それぞれ有効である。 The melanin production inhibitor of the present invention is used to treat, improve and prevent pigmentation, the collagen production promoter is used to treat, improve and prevent osteoporosis, arthritis, tendonitis and wounds, and the antioxidant is used to treat diseases caused by oxidative stress. and for the treatment, improvement and prevention of skin aging.

本発明に用いるオオヨモギ(Artemisia montana)は、キク科ヨモギ属の多年草で、主に本州(近畿地方以北)、北海道に自生している。一方、ヨモギ(Artemisia princepsあるいはArtemisia indica)は、主に本州~九州、小笠原に分布し、植物体の大きさ(例えば、茎の高さ、頭花の径、葉の長さ等)は本発明のオオヨモギより小形であり、オオヨモギとは異なる種の植物である。なお、Artemisia princepsとArtemisia indicaとはシノニム(Synonym)の関係になる。 Artemisia montana used in the present invention is a perennial plant of the family Asteraceae, genus Artemisia, and grows naturally in Honshu (north of the Kinki region) and Hokkaido. On the other hand, Artemisia princeps or Artemisia indica is mainly distributed in Honshu to Kyushu and Ogasawara, and the plant size (e.g., stem height, flower head diameter, leaf length, etc.) is different from that of the present invention. It is smaller than the Japanese mugwort, and is a different species of plant from the Japanese mugwort. Note that Artemisia princeps and Artemisia indica have a synonymous relationship.

本発明に用いるオオヨモギは、上記の生育地域からも入手することができるし、市販品を購入することもできる。抽出原料として使用するオオヨモギの部位は、全草であっても良いし、その一部であっても良いが、効果の面から、葉部が好ましい。また、抽出には、植物体を生のまま使用しても良く、乾燥、粉砕、細切等の処理を行っても良い。 The mugwort used in the present invention can be obtained from the above-mentioned growing regions, or can be purchased commercially. The part of Mugwort used as an extraction raw material may be the whole plant or a part thereof, but from the viewpoint of effectiveness, the leaf part is preferable. Further, for extraction, the plant body may be used raw, or may be subjected to treatments such as drying, pulverization, and shredding.

本発明の抽出物に用いる抽出溶媒としては、例えば、水、低級アルコール類(メタノール、エタノール、1-プロパノール、2-プロパノール、1-ブタノール、2-ブタノール等)、液状多価アルコール類(1,3-ブチレングリコール、プロピレングリコール、グリセリン等)、ケトン類(アセトン、メチルエチルケトン等)、アセトニトリル、エステル類(酢酸エチル、酢酸ブチル等)、炭化水素類(ヘキサン、ヘプタン、流動パラフィン等)、エーテル類(エチルエーテル、テトラヒドロフラン、プロピルエーテル等)が挙げられる。好ましくは、水、低級アルコール及び液状多価アルコール等の極性溶媒が良く、特に好ましくは、水、エタノール、1,3-ブチレングリコール及びプロピレングリコールが良い。これらの溶媒は一種でも二種以上を混合して用いても良い。また、これらの溶媒に酸やアルカリを添加して、pHを調整した溶媒を用いることもできる。また、抽出方法は、特に限定されないが、例えば、連続抽出や浸漬抽出が挙げられる。抽出温度は、加熱抽出であっても良いし、常温抽出や冷温抽出であっても良く、抽出物の使用用途や抽出溶媒等によって、適宜選択できる。 Extraction solvents used in the extract of the present invention include, for example, water, lower alcohols (methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, etc.), liquid polyhydric alcohols (1, 3-butylene glycol, propylene glycol, glycerin, etc.), ketones (acetone, methyl ethyl ketone, etc.), acetonitrile, esters (ethyl acetate, butyl acetate, etc.), hydrocarbons (hexane, heptane, liquid paraffin, etc.), ethers ( ethyl ether, tetrahydrofuran, propyl ether, etc.). Polar solvents such as water, lower alcohols and liquid polyhydric alcohols are preferred, and water, ethanol, 1,3-butylene glycol and propylene glycol are particularly preferred. These solvents may be used alone or in combination of two or more. Moreover, it is also possible to use a solvent whose pH is adjusted by adding an acid or an alkali to these solvents. Moreover, the extraction method is not particularly limited, and examples thereof include continuous extraction and immersion extraction. The extraction temperature may be heated extraction, room temperature extraction, or cold temperature extraction, and can be appropriately selected depending on the intended use of the extract, the extraction solvent, and the like.

本発明の抽出物は、抽出した溶液のまま用いても良いが、必要に応じて、本発明の効果を奏する範囲で、濃縮(減圧濃縮、膜濃縮等による濃縮)、希釈、濾過、活性炭等による脱色、脱臭等の処理を行ってから用いても良い。更には、抽出した溶液を濃縮乾固、噴霧乾燥、凍結乾燥等の処理を行い、乾燥物として用いても良い。 The extract of the present invention may be used as an extracted solution, but if necessary, concentration (concentration by vacuum concentration, membrane concentration, etc.), dilution, filtration, activated carbon, etc. It may be used after being subjected to treatments such as decolorization and deodorization. Furthermore, the extracted solution may be subjected to treatments such as concentration to dryness, spray drying, freeze drying, etc., and used as a dried product.

本発明のメラニン生成抑制剤、コラーゲン産生促進剤、抗酸化剤及び食品組成物は、上記抽出物をそのまま使用しても良く、抽出物の効果を損なわない範囲内で、化粧品、医薬部外品、医薬品又は食品等に用いられる成分である油脂類、ロウ類、炭化水素類、脂肪酸類、アルコール類、エステル類、界面活性剤、金属石鹸、pH調整剤、防腐剤、香料、保湿剤、粉体、紫外線吸収剤、増粘剤、色素、酸化防止剤、美白剤、キレート剤、賦形剤、皮膜剤、甘味料、酸味料等の成分が含有されていても良い。 The melanin production inhibitor, collagen production promoter, antioxidant, and food composition of the present invention may be used in cosmetics, quasi-drugs, etc., as long as the above-mentioned extracts may be used as they are, and the effects of the extracts are not impaired. , oils and fats, waxes, hydrocarbons, fatty acids, alcohols, esters, surfactants, metal soaps, pH adjusters, preservatives, fragrances, moisturizers, powders used in pharmaceuticals or foods, etc. The composition may contain components such as a UV absorber, a thickener, a pigment, an antioxidant, a whitening agent, a chelating agent, an excipient, a coating agent, a sweetener, and an acidulant.

本発明のメラニン生成抑制剤、コラーゲン産生促進剤、抗酸化剤及び食品組成物の剤形としては、例えば、化粧水、クリーム、乳液、ゲル剤、エアゾール剤、エッセンス、パック、洗浄剤、浴用剤、ファンデーション、打粉、口紅、軟膏、パップ剤、錠菓、カプセル剤、チョコレート、ガム、飴、飲料、散剤、顆粒剤、錠剤、糖衣錠剤、カプセル剤、シロップ剤、丸剤、懸濁剤、液剤、乳剤、坐剤、注射用溶液等が挙げられる。 Dosage forms of the melanin production inhibitor, collagen production promoter, antioxidant, and food composition of the present invention include, for example, lotions, creams, emulsions, gels, aerosols, essences, packs, cleaning agents, and bath preparations. , foundation, powder, lipstick, ointment, poultice, tablet, capsule, chocolate, gum, candy, beverage, powder, granule, tablet, sugar-coated tablet, capsule, syrup, pill, suspension, liquid , emulsions, suppositories, solutions for injection, etc.

外用の場合、本発明に用いる上記抽出物の含有量は、固形物に換算して0.0001重量%以上が好ましく、0.001~10重量%がより好ましい。更に、0.01~5重量%が最も好ましい。0.0001重量%未満では十分な効果は望みにくい。10重量%を越えると、効果の増強は認められにくく不経済である。 For external use, the content of the extract used in the present invention is preferably 0.0001% by weight or more, more preferably 0.001 to 10% by weight, in terms of solid matter. Furthermore, 0.01 to 5% by weight is most preferred. If it is less than 0.0001% by weight, it is difficult to expect sufficient effects. If it exceeds 10% by weight, it is difficult to notice any enhancement of the effect and it is uneconomical.

内用の場合、摂取量は年齢、体重、症状、治療効果、投与方法、処理時間等により異なる。通常、成人1人当たりの1日の摂取量としては、5mg以上が好ましく、10mg~5gがより好ましい。更に、20mg~2gが最も好ましい。 For internal use, the intake amount varies depending on age, body weight, symptoms, therapeutic effect, administration method, treatment time, etc. Usually, the daily intake per adult is preferably 5 mg or more, more preferably 10 mg to 5 g. Furthermore, 20 mg to 2 g is most preferred.

次に、実施例により本発明を更に具体的に説明するが、本発明はこれに限定されるものではない。なお、特に指定のない場合は、実施例に示す%とは重量%を示す。 Next, the present invention will be explained in more detail with reference to Examples, but the present invention is not limited thereto. In addition, unless otherwise specified, % shown in Examples indicates weight %.

(製造例1)オオヨモギの熱水抽出物1の調製
オオヨモギ(Artemisia montana)の葉の乾燥物10gに200mLの水を加え、95~100℃で2時間抽出した。得られた抽出液を濾過し、その濾液を濃縮し、凍結乾燥してオオヨモギの熱水抽出物1を1.7g得た。
(Production Example 1) Preparation of Hot Water Extract 1 of Artemisia montana 200 mL of water was added to 10 g of dried leaves of Artemisia montana and extracted at 95 to 100°C for 2 hours. The obtained extract was filtered, and the filtrate was concentrated and freeze-dried to obtain 1.7 g of hot water extract 1 of Mugwort trifoliata.

(製造例2)オオヨモギの50%エタノール抽出物の調製
オオヨモギ(Artemisia montana)の葉の乾燥物10gを200mLの50%エタノール水溶液に室温で7日間浸漬し抽出を行った。得られた抽出液を濾過した後、エバポレーターで濃縮乾固してオオヨモギの50%エタノール抽出物を2.1g得た。
(Production Example 2) Preparation of 50% ethanol extract of Artemisia montana 10 g of dried leaves of Artemisia montana was extracted by immersing it in 200 mL of a 50% ethanol aqueous solution at room temperature for 7 days. After filtering the obtained extract, it was concentrated to dryness using an evaporator to obtain 2.1 g of a 50% ethanol extract of Artemisia annua.

(製造例3)オオヨモギのエタノール抽出物の調製
オオヨモギ(Artemisia montana)の葉の乾燥物10gを200mLのエタノールに室温で7日間浸漬し抽出を行った。得られた抽出液を濾過した後、エバポレーターで濃縮乾固してオオヨモギのエタノール抽出物を0.5g得た。
(Production Example 3) Preparation of Ethanol Extract of Artemisia montana 10 g of dried Artemisia montana leaves was immersed in 200 mL of ethanol at room temperature for 7 days for extraction. After filtering the obtained extract, it was concentrated to dryness using an evaporator to obtain 0.5 g of an ethanol extract of Mugwort trifoliata.

(製造例4)オオヨモギの1,3-ブチレングリコール抽出物の調製
オオヨモギ(Artemisia montana)の葉の乾燥物10gを200mLの1,3-ブチレングリコールに室温で7日間浸漬し抽出を行った。得られた抽出液を濾過してオオヨモギの1,3-ブチレングリコール抽出物を192g得た。
(Production Example 4) Preparation of 1,3-butylene glycol extract of Artemisia montana 10 g of dried leaves of Artemisia montana was immersed in 200 mL of 1,3-butylene glycol at room temperature for 7 days for extraction. The obtained extract was filtered to obtain 192 g of a 1,3-butylene glycol extract of Artemisia annua.

(製造例5)オオヨモギの熱水抽出物2の調製
オオヨモギ(Artemisia montana)の全草の乾燥物10gに200mLの水を加え、95~100℃で2時間抽出した。得られた抽出液を濾過し、その濾液を濃縮し、凍結乾燥してオオヨモギの熱水抽出物2を1.8g得た。
(Production Example 5) Preparation of Hot Water Extract 2 of Artemisia montana 200 mL of water was added to 10 g of dried whole plant of Artemisia montana and extracted at 95 to 100°C for 2 hours. The obtained extract was filtered, and the filtrate was concentrated and freeze-dried to obtain 1.8 g of Hot Water Extract 2 of Mugwort.

(比較製造例1)ヨモギの熱水抽出物の調製
ヨモギ(Artemisia princeps)の乾燥物10gに200mLの水を加え、95~100℃で2時間抽出した。得られた抽出液を濾過し、その濾液を濃縮し、凍結乾燥してヨモギの熱水抽出物を1.7g得た。
(Comparative Production Example 1) Preparation of hot water extract of Artemisia princeps 200 mL of water was added to 10 g of dried Artemisia princeps, and extracted at 95 to 100° C. for 2 hours. The obtained extract was filtered, and the filtrate was concentrated and freeze-dried to obtain 1.7 g of a hot water extract of mugwort.

(比較製造例2)ヨモギの50%エタノール抽出物の調製
ヨモギ(Artemisia princeps)の乾燥物10gを200mLの50%エタノール水溶液に室温で7日間浸漬し抽出を行った。得られた抽出液を濾過した後、エバポレーターで濃縮乾固してヨモギの50%エタノール抽出物を1.4g得た。
(Comparative Production Example 2) Preparation of 50% ethanol extract of Artemisia princeps 10 g of dried Artemisia princeps was immersed in 200 mL of a 50% ethanol aqueous solution at room temperature for 7 days for extraction. After filtering the obtained extract, it was concentrated to dryness using an evaporator to obtain 1.4 g of a 50% ethanol extract of Artemisia annua.

(比較製造例3)ヨモギのエタノール抽出物の調製
ヨモギ(Artemisia princeps)の乾燥物10gを200mLのエタノールに室温で7日間浸漬し抽出を行った。得られた抽出液を濾過した後、エバポレーターで濃縮乾固してヨモギのエタノール抽出物を0.4g得た。
(Comparative Production Example 3) Preparation of Ethanol Extract of Artemisia princeps 10 g of dried Artemisia princeps was immersed in 200 mL of ethanol at room temperature for 7 days for extraction. After filtering the obtained extract, it was concentrated to dryness using an evaporator to obtain 0.4 g of an ethanolic extract of mugwort.

(処方例1) 化粧水1
処方 含有量(%)
1.オオヨモギの熱水抽出物1(製造例1) 2.0
2.1,3-ブチレングリコール 8.0
3.グリセリン 2.0
4.キサンタンガム 0.02
5.クエン酸 0.01
6.クエン酸ナトリウム 0.1
7.エタノール 5.0
8.パラオキシ安息香酸メチル 0.1
9.ポリオキシエチレン硬化ヒマシ油(40E.O.) 0.1
10.香料 適量
11.精製水にて全量を100とする
[製造方法]成分1~6及び11と、成分7~10をそれぞれ均一に溶解し、両者を混合し濾過して製品とする。
(Prescription example 1) Lotion 1
Prescription Content (%)
1. Hot water extract of mugwort 1 (manufacturing example 1) 2.0
2.1,3-butylene glycol 8.0
3. Glycerin 2.0
4. Xanthan gum 0.02
5. Citric acid 0.01
6. Sodium citrate 0.1
7. Ethanol 5.0
8. Methyl paraoxybenzoate 0.1
9. Polyoxyethylene hydrogenated castor oil (40E.O.) 0.1
10. Fragrance: Appropriate amount 11. Make the total amount 100% with purified water. [Manufacturing method] Components 1 to 6 and 11 and components 7 to 10 are each uniformly dissolved, mixed and filtered to obtain a product.

(処方例2) 化粧水2
処方例1において、オオヨモギの熱水抽出物1をオオヨモギの熱水抽出物2(製造例5)に置き換えたものを処方例2とした。
(Prescription example 2) Lotion 2
Formulation Example 2 was prepared by replacing Hot Water Extract 1 of Artemisia mugwort in Formulation Example 1 with Hot Water Extract 2 of Artemisia mugwort (Manufacturing Example 5).

(処方例3) クリーム
処方 含有量(%)
1.オオヨモギの50%エタノール抽出物(製造例2) 1.0
2.スクワラン 5.5
3.オリーブ油 3.0
4.ステアリン酸 2.0
5.ミツロウ 2.0
6.ミリスチン酸オクチルドデシル 3.5
7.ポリオキシエチレンセチルエーテル(20E.O.) 3.0
8.ベヘニルアルコール 1.5
9.モノステアリン酸グリセリン 2.5
10.香料 0.1
11.パラオキシ安息香酸メチル 0.2
12.1,3-ブチレングリコール 8.5
13.精製水にて全量を100とする
[製造方法]成分2~9を加熱溶解して混合し、70℃に保ち油相とする。成分1及び11~13を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら冷却し、45℃で成分10を加え、更に30℃まで冷却して製品とする。
(Prescription example 3) Cream prescription Content (%)
1. 50% ethanol extract of mugwort (manufacturing example 2) 1.0
2. Squalane 5.5
3. Olive oil 3.0
4. Stearic acid 2.0
5. Beeswax 2.0
6. Octyldodecyl myristate 3.5
7. Polyoxyethylene cetyl ether (20E.O.) 3.0
8. Behenyl alcohol 1.5
9. Glyceryl monostearate 2.5
10. Fragrance 0.1
11. Methyl paraoxybenzoate 0.2
12.1,3-butylene glycol 8.5
13. Make the total amount 100% with purified water. [Manufacturing method] Components 2 to 9 are dissolved and mixed by heating, and kept at 70°C to form an oil phase. Components 1 and 11 to 13 are heated and dissolved, mixed, and kept at 75°C to form an aqueous phase. Add the aqueous phase to the oil phase and emulsify, cool while stirring, add component 10 at 45°C, and further cool to 30°C to obtain a product.

(処方例4) 乳液
処方 含有量(%)
1.オオヨモギのエタノール抽出物(製造例3) 0.01
2.スクワラン 5.0
3.オリーブ油 5.0
4.ホホバ油 5.0
5.セタノール 1.5
6.モノステアリン酸グリセリン 2.0
7.ポリオキシエチレンセチルエーテル(20E.O.) 3.0
8.ポリオキシエチレンソルビタンモノオレエート(20E.O.) 2.0
9.香料 0.1
10.プロピレングリコール 1.0
11.グリセリン 2.0
12.パラオキシ安息香酸メチル 0.2
13.精製水にて全量を100とする
[製造方法]成分1~8を加熱溶解して混合し、70℃に保ち油相とする。成分10~13を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら冷却し、45℃で成分9を加え、更に30℃まで冷却して製品とする。
(Formulation example 4) Emulsion Prescription Content (%)
1. Ethanol extract of mugwort (manufacturing example 3) 0.01
2. Squalane 5.0
3. Olive oil 5.0
4. Jojoba oil 5.0
5. Setanol 1.5
6. Glyceryl monostearate 2.0
7. Polyoxyethylene cetyl ether (20E.O.) 3.0
8. Polyoxyethylene sorbitan monooleate (20E.O.) 2.0
9. Fragrance 0.1
10. Propylene glycol 1.0
11. Glycerin 2.0
12. Methyl paraoxybenzoate 0.2
13. Make the total amount 100% with purified water. [Manufacturing method] Components 1 to 8 are dissolved and mixed by heating, and kept at 70°C to form an oil phase. Components 10 to 13 are dissolved and mixed by heating, and the mixture is kept at 75°C to form an aqueous phase. Add the aqueous phase to the oil phase and emulsify, cool while stirring, add component 9 at 45°C, and further cool to 30°C to obtain a product.

(処方例5) ゲル剤
処方 含有量(%)
1.オオヨモギの1,3-ブチレングリコール抽出物(製造例4) 1.0
2.エタノール 5.0
3.パラオキシ安息香酸メチル 0.1
4.ポリオキシエチレン硬化ヒマシ油(60E.O.) 0.1
5.香料 適量
6.1,3-ブチレングリコール 5.0
7.グリセリン 5.0
8.キサンタンガム 0.1
9.カルボキシビニルポリマー 0.2
10.水酸化カリウム 0.2
11.精製水にて全量を100とする
[製造方法]成分2~5と、成分1及び6~11をそれぞれ均一に溶解し、両者を混合して製品とする。
(Formulation example 5) Gel formulation Content (%)
1. 1,3-butylene glycol extract of mugwort (manufacturing example 4) 1.0
2. Ethanol 5.0
3. Methyl paraoxybenzoate 0.1
4. Polyoxyethylene hydrogenated castor oil (60E.O.) 0.1
5. Fragrance Appropriate amount 6.1,3-butylene glycol 5.0
7. Glycerin 5.0
8. Xanthan gum 0.1
9. Carboxyvinyl polymer 0.2
10. Potassium hydroxide 0.2
11. Make the total amount 100% with purified water. [Manufacturing method] Components 2 to 5 and components 1 and 6 to 11 are each uniformly dissolved and mixed to form a product.

(処方例6) パック
処方 含有量(%)
1.オオヨモギの熱水抽出物1(製造例1) 1.0
2.オオヨモギの1,3-ブチレングリコール抽出物(製造例4) 5.0
3.ポリビニルアルコール 12.0
4.エタノール 5.0
5.1,3-ブチレングリコール 8.0
6.パラオキシ安息香酸メチル 0.2
7.ポリオキシエチレン硬化ヒマシ油(20E.O.) 0.5
8.クエン酸 0.1
9.クエン酸ナトリウム 0.3
10.香料 適量
11.精製水にて全量を100とする
[製造方法]成分1~11を均一に溶解し製品とする。
(Formulation example 6) Pack prescription Content (%)
1. Hot water extract of mugwort 1 (manufacturing example 1) 1.0
2. 1,3-butylene glycol extract of mugwort (manufacturing example 4) 5.0
3. Polyvinyl alcohol 12.0
4. Ethanol 5.0
5.1,3-butylene glycol 8.0
6. Methyl paraoxybenzoate 0.2
7. Polyoxyethylene hydrogenated castor oil (20E.O.) 0.5
8. Citric acid 0.1
9. Sodium citrate 0.3
10. Fragrance: Appropriate amount 11. Make the total amount 100% with purified water. [Manufacturing method] Components 1 to 11 are uniformly dissolved to form a product.

(処方例7) ファンデーション
処方 含有量(%)
1.オオヨモギの50%エタノール抽出物(製造例2) 1.0
2.ステアリン酸 2.4
3.ポリオキシエチレンソルビタンモノステアレート(20E.O.) 1.0
4.ポリオキシエチレンセチルエーテル(20E.O.) 2.0
5.セタノール 1.0
6.液状ラノリン 2.0
7.流動パラフィン 3.0
8.ミリスチン酸イソプロピル 6.5
9.カルボキシメチルセルロースナトリウム 0.1
10.ベントナイト 0.5
11.プロピレングリコール 4.0
12.トリエタノールアミン 1.1
13.パラオキシ安息香酸メチル 0.2
14.二酸化チタン 8.0
15.タルク 4.0
16.ベンガラ 1.0
17.黄酸化鉄 2.0
18.香料 適量
19.精製水にて全量を100とする
[製造方法]成分2~8を加熱溶解し、80℃に保ち油相とする。成分19に成分9をよく膨潤させ、続いて、成分1及び10~13を加えて均一に混合する。これに粉砕機で粉砕混合した成分14~17を加え、ホモミキサーで撹拌し75℃に保ち水相とする。この油相に水相をかき混ぜながら加え、乳化する。その後、冷却し、45℃で成分18を加え、かき混ぜながら30℃まで冷却して製品とする。
(Prescription Example 7) Foundation Prescription Content (%)
1. 50% ethanol extract of mugwort (manufacturing example 2) 1.0
2. Stearic acid 2.4
3. Polyoxyethylene sorbitan monostearate (20E.O.) 1.0
4. Polyoxyethylene cetyl ether (20E.O.) 2.0
5. Setanol 1.0
6. liquid lanolin 2.0
7. Liquid paraffin 3.0
8. Isopropyl myristate 6.5
9. Carboxymethyl cellulose sodium 0.1
10. Bentonite 0.5
11. Propylene glycol 4.0
12. Triethanolamine 1.1
13. Methyl paraoxybenzoate 0.2
14. Titanium dioxide 8.0
15. Talc 4.0
16. Bengala 1.0
17. Yellow iron oxide 2.0
18. Fragrance: Appropriate amount 19. Make the total amount 100% with purified water. [Production method] Dissolve components 2 to 8 by heating and keep at 80°C to form an oil phase. Component 9 is sufficiently swollen in component 19, and then components 1 and 10 to 13 are added and mixed uniformly. Add components 14 to 17 that have been ground and mixed using a grinder, stir with a homomixer, and keep at 75°C to form an aqueous phase. Add the aqueous phase to the oil phase while stirring and emulsify. Thereafter, it is cooled, and component 18 is added at 45°C, and the mixture is cooled to 30°C while stirring to form a product.

(処方例8) 浴用剤
処方 含有量(%)
1.オオヨモギのエタノール抽出物(製造例3) 1.0
2.炭酸水素ナトリウム 50.0
3.黄色202号(1) 適量
4.香料 適量
5.硫酸ナトリウムにて全量を100とする
[製造方法]成分1~5を均一に混合し製品とする。
(Prescription example 8) Bath additive Prescription Content (%)
1. Ethanol extract of mugwort (manufacturing example 3) 1.0
2. Sodium hydrogen carbonate 50.0
3. Yellow No. 202 (1) Appropriate amount 4. Fragrance (appropriate amount) 5. Adjust the total amount to 100% with sodium sulfate. [Manufacturing method] Mix components 1 to 5 uniformly to make a product.

(処方例9) 軟膏
処方 含有量(%)
1.オオヨモギの1,3-ブチレングリコール抽出物(製造例4) 1.0
2.オオヨモギの熱水抽出物2(製造例5) 5.0
3.ポリオキシエチレンセチルエーテル(30E.O.) 2.0
4.モノステアリン酸グリセリン 10.0
5.流動パラフィン 5.0
6.セタノール 6.0
7.パラオキシ安息香酸メチル 0.1
8.プロピレングリコール 10.0
9.精製水にて全量を100とする
[製造方法]成分3~6を加熱溶解して混合し、70℃に保ち油相とする。成分1、2及び7~9を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら30℃まで冷却して製品とする。
(Prescription example 9) Ointment Prescription Content (%)
1. 1,3-butylene glycol extract of mugwort (manufacturing example 4) 1.0
2. Hot water extract of mugwort 2 (manufacturing example 5) 5.0
3. Polyoxyethylene cetyl ether (30E.O.) 2.0
4. Glyceryl monostearate 10.0
5. Liquid paraffin 5.0
6. Setanol 6.0
7. Methyl paraoxybenzoate 0.1
8. Propylene glycol 10.0
9. Make the total amount 100% with purified water. [Manufacturing method] Components 3 to 6 are dissolved and mixed by heating, and kept at 70°C to form an oil phase. Components 1, 2, and 7 to 9 are mixed by heating and kept at 75°C to form an aqueous phase. Add the aqueous phase to the oil phase, emulsify, and cool to 30°C while stirring to obtain a product.

(処方例10) 散剤1
処方 含有量(%)
1.オオヨモギの熱水抽出物1(製造例1) 1.0
2.乾燥コーンスターチ 39.0
3.微結晶セルロース 60.0
[製造方法]成分1~3を混合し、製品とする。
(Prescription example 10) Powder 1
Prescription Content (%)
1. Hot water extract of mugwort 1 (manufacturing example 1) 1.0
2. Dried cornstarch 39.0
3. Microcrystalline cellulose 60.0
[Manufacturing method] Components 1 to 3 are mixed to form a product.

(処方例11) 散剤2
処方例10において、オオヨモギの熱水抽出物1(製造例1)をオオヨモギの熱水抽出物2(製造例5)に置き換えたものを散剤2とした。
(Prescription example 11) Powder 2
In Formulation Example 10, Powder 2 was prepared by replacing hot water extract 1 of Mugwort grandiflorum (Production Example 1) with hot water extract 2 of Artemisia grandiflora (Production Example 5).

(処方例12) 散剤3
処方例10において、オオヨモギの熱水抽出物1(製造例1)をオオヨモギの50%エタノール抽出物(製造例2)に置き換えたものを散剤3とした。
(Prescription example 12) Powder 3
In Formulation Example 10, Powder 3 was prepared by replacing the hot water extract 1 (Manufacturing Example 1) of Artemisia mugwort with 50% ethanol extract (Manufacturing Example 2).

(処方例13) 錠剤
処方 含有量(%)
1.オオヨモギのエタノール抽出物(製造例3) 5.0
2.乾燥コーンスターチ 25.0
3.カルボキシメチルセルロースカルシウム 20.0
4.微結晶セルロース 40.0
5.ポリビニルピロリドン 7.0
6.タルク 3.0
[製造方法]成分1~4を混合し、次いで成分5の水溶液を結合剤として加えて顆粒成型する。成型した顆粒に成分6を加えて打錠する。1錠0.52gとする。
(Prescription Example 13) Tablet Prescription Content (%)
1. Ethanol extract of mugwort (manufacturing example 3) 5.0
2. Dried cornstarch 25.0
3. Carboxymethyl cellulose calcium 20.0
4. Microcrystalline cellulose 40.0
5. Polyvinylpyrrolidone 7.0
6. Talc 3.0
[Manufacturing method] Components 1 to 4 are mixed, then an aqueous solution of component 5 is added as a binder, and granules are formed. Add ingredient 6 to the molded granules and tablet. One tablet weighs 0.52 g.

(処方例14) 錠菓1
処方 含有量(%)
1.オオヨモギのエタノール抽出物(製造例3) 2.0
2.乾燥コーンスターチ 49.8
3.エリスリトール 40.0
4.クエン酸 5.0
5.ショ糖脂肪酸エステル 3.0
6.香料 0.1
7.精製水 0.1
[製造方法]成分1~4及び7を混合し、顆粒成型する。成型した顆粒に成分5及び6を加えて打錠する。1粒1.0gとする。
(Prescription example 14) Tablet confectionery 1
Prescription Content (%)
1. Ethanol extract of mugwort (manufacturing example 3) 2.0
2. Dried cornstarch 49.8
3. Erythritol 40.0
4. Citric acid 5.0
5. Sucrose fatty acid ester 3.0
6. Fragrance 0.1
7. Purified water 0.1
[Production method] Components 1 to 4 and 7 are mixed and formed into granules. Components 5 and 6 are added to the molded granules and compressed into tablets. One grain is 1.0g.

(処方例15) 錠菓2
処方例14において、オオヨモギのエタノール抽出物(製造例3)をオオヨモギの熱水抽出物2(製造例5)に置き換えたものを錠菓2とした。
(Prescription example 15) Tablet confectionery 2
Tablet confectionery 2 was prepared by replacing the ethanol extract of Mugwort artemis (Manufacturing example 3) with the hot water extract of Artemisia artemis 2 (Manufacturing example 5) in Formulation example 14.

(処方例16) 錠菓3
処方例14において、オオヨモギのエタノール抽出物(製造例3)をオオヨモギの50%エタノール抽出物(製造例2)に置き換えたものを錠菓3とした。
(Prescription example 16) Tablet confectionery 3
Tablet confectionery 3 was prepared by replacing the ethanol extract of mugwort (Manufacturing Example 3) with the 50% ethanol extract of mugwort (manufacturing example 2) in Formulation Example 14.

(処方例17) 飲料
処方 含有量(%)
1.オオヨモギの熱水抽出物1(製造例1) 0.05
2.ステビア 0.05
3.リンゴ酸 5.0
4.香料 0.1
5.精製水 94.8
[製造方法]成分2及び3を少量の水に溶解する。次いで、成分1、4及び5を加えて混合する。
(Formulation example 17) Beverage prescription Content (%)
1. Hot water extract of mugwort 1 (manufacturing example 1) 0.05
2. Stevia 0.05
3. Malic acid 5.0
4. Fragrance 0.1
5. Purified water 94.8
[Manufacturing method] Components 2 and 3 are dissolved in a small amount of water. Then add and mix ingredients 1, 4 and 5.

実験例1 メラニン生成抑制試験
対数増殖期にあるB16マウスメラノーマを60mmdishに3×10個播種し、各試料(終濃度は表1に記載)を含むEagle’s MEM(10%FBS含有)培地にて、37℃、5%COの条件下で5日間培養した。次に、細胞をdishから剥離し、超音波破砕した後、4N NaOHを加え60℃で2時間の処理を行い、分光光度計を用いて475nmにおける吸光度を測定することでメラニンを定量した。なお、超音波処理後の細胞破砕液についてLowryの方法(J.Biol.Chem.,193,265-275,1951)にてタンパク定量し、タンパク量当りのメラニン量を算出すると共に、試料未添加時のメラニン量をコントロールとし、コントロールに対する試料添加時のメラニン量の値から、メラニン生成抑制率を算出した。
Experimental Example 1 Melanin Production Suppression Test 3 x 104 B16 mouse melanomas in the logarithmic growth phase were seeded in a 60 mm dish, and Eagle's MEM (containing 10% FBS) medium containing each sample (the final concentration is listed in Table 1) was used. The cells were cultured for 5 days at 37° C. and 5% CO 2 . Next, the cells were detached from the dish and disrupted by ultrasonication, then treated with 4N NaOH at 60° C. for 2 hours, and melanin was quantified by measuring absorbance at 475 nm using a spectrophotometer. In addition, protein was quantified using the method of Lowry (J. Biol. Chem., 193, 265-275, 1951) for the cell homogenate after ultrasonic treatment, and the amount of melanin per amount of protein was calculated. The melanin amount at the time of sample addition was used as a control, and the melanin production inhibition rate was calculated from the value of the melanin amount at the time of sample addition relative to the control.

この試験結果を表1に示した。本発明のオオヨモギの抽出物は、ヨモギの抽出物よりも顕著に優れたメラニン生成抑制効果を有していることが認められた。なお、ヨモギのエタノール抽出物については、10μg/mLで細胞毒性が認められた。これに対して、オオヨモギのエタノール抽出物は、同濃度でも細胞毒性は認められず、優れたメラニン生成抑制効果を示したことから、安全性についても優れていることが確認された。 The test results are shown in Table 1. It was found that the extract of Artemisia annua of the present invention has a melanin production inhibiting effect that is significantly superior to that of the extract of Artemisia annua. It should be noted that cytotoxicity was observed at 10 μg/mL of the ethanolic extract of Mugwort. On the other hand, the ethanol extract of Mugwort albicans showed no cytotoxicity even at the same concentration and exhibited excellent melanin production inhibiting effects, confirming its superior safety.

実験例2 コラーゲン産生促進試験
COL1A1 mRNA発現量の測定を行った。ヒト皮膚線維芽細胞を60mm dishに1×10個播種し、10%FBSを含むDMEM培養液にて、37℃、5%CO条件下で培養した。コンフルエントな状態になったところで、各試料(終濃度は表2に記載)を添加したDMEM(-)培養液にて24時間培養した後、総RNAの抽出を行った。細胞からの総RNAの抽出はRNAiso Plus(タカラバイオ)を用いて行い、総RNA量は分光光度計(NanoDrop)を用いて260nmにおける吸光度により求めた。mRNA発現量の測定は、細胞から抽出した総RNAを基にしてリアルタイムRT-PCR法により行った。リアルタイムRT-PCR法には、High Capacity RNA-to-cDNA Kit(Applied Biosystems)及びSYBR Select Master Mix(Applied Biosystems)を用いた。即ち、500ngの総RNAを逆転写反応後、PCR反応(95℃:15秒間、60℃:60秒間、40cycles)を行った。その他の操作は定められた方法に従い、COL1A1 mRNAの発現量を、内部標準であるβ―actin mRNAの発現量に対する割合として求めた。COL1A1発現促進率は、コントロール(試料未添加)群のCOL1A1 mRNAの発現量に対する試料添加群のCOL1A1 mRNAの発現量の比率として算出した。なお、各遺伝子の発現量の測定に使用したプライマーは次の通りである。
Experimental Example 2 Collagen Production Promotion Test COL1A1 mRNA expression level was measured. 1 x 10 5 human skin fibroblasts were seeded in a 60 mm dish and cultured in a DMEM culture medium containing 10% FBS at 37°C and 5% CO 2 . When a confluent state was reached, the cells were cultured for 24 hours in a DMEM (-) culture medium supplemented with each sample (final concentration listed in Table 2), and then total RNA was extracted. Total RNA was extracted from cells using RNAiso Plus (Takara Bio), and the amount of total RNA was determined by absorbance at 260 nm using a spectrophotometer (NanoDrop). The mRNA expression level was measured by real-time RT-PCR based on total RNA extracted from cells. For the real-time RT-PCR method, High Capacity RNA-to-cDNA Kit (Applied Biosystems) and SYBR Select Master Mix (Applied Biosystems) were used. That is, after reverse transcription reaction of 500 ng of total RNA, PCR reaction (95°C: 15 seconds, 60°C: 60 seconds, 40 cycles) was performed. Other operations were performed in accordance with established methods, and the expression level of COL1A1 mRNA was determined as a ratio to the expression level of β-actin mRNA, which is an internal standard. The COL1A1 expression promotion rate was calculated as the ratio of the expression level of COL1A1 mRNA in the sample added group to the expression level of COL1A1 mRNA in the control (no sample added) group. The primers used to measure the expression level of each gene are as follows.

COL1A1用のプライマーセット
AGGACAAGAGGCATGTCTGGTT(配列番号1)
TTGCAGTGGTAGGTGATGTTCTG(配列番号2)
β―actin用のプライマーセット
CACTCTTCCAGCCTTCCTTCC(配列番号3)
GTGTTGGCGTACAGGTCTTTG(配列番号4)
Primer set AGGACAAGAGGCATGTCTGGTT for COL1A1 (SEQ ID NO: 1)
TTGCAGTGGTAGGTGATGTTCTG (SEQ ID NO: 2)
Primer set for β-actin CACTCTTCCAGCCTTCCTTCC (SEQ ID NO: 3)
GTGTTGGCGTACAGGTCTTTG (SEQ ID NO: 4)

この実験結果を表2に示した。その結果、本発明のオオヨモギの抽出物は、ヨモギの抽出物よりも顕著に優れたコラーゲン産生促進効果を有していることが認められた。 The results of this experiment are shown in Table 2. As a result, it was found that the extract of Mugwort of the present invention had a significantly superior collagen production promoting effect than the extract of Mugwort.

実験例3 DPPHラジカル消去試験(抗酸化試験)
活性酸素種として、安定なフリーラジカルであるα,α-ジフェニル-β-ピクリルヒドラジル(以下DPPHとする)を用い、試料と一定の割合で一定時間反応させ、減少するDPPHの量を、分光光度計を用いて517nmにおける吸光度の減少量から測定した。
Experimental example 3 DPPH radical scavenging test (antioxidant test)
α,α-diphenyl-β-picrylhydrazyl (hereinafter referred to as DPPH), which is a stable free radical, is used as the active oxygen species, and is reacted with the sample at a certain rate for a certain period of time, and the amount of DPPH that decreases is determined by The amount of decrease in absorbance at 517 nm was measured using a spectrophotometer.

DPPHラジカル消去効果の測定方法
各試料(終濃度は表3に記載)を添加した0.1M酢酸緩衝液(pH5.5)0.4mLに無水エタノール0.4mL及び0.5mM DPPH無水エタノール溶液0.2mLを加えて反応液とした。また、油溶性の試料の場合は無水エタノール0.4mLに試料を加えて反応液とした。その後、37℃で30分間反応させ、水を対照として517nmの吸光度(A)を測定した。また、コントロールとして試料の代わりに精製水を用いて吸光度(B)を測定した。DPPHラジカル消去率は、以下に示す式より算出した。
DPPHラジカル消去率(%)=(1-A/B)×100
Method for measuring DPPH radical scavenging effect Add 0.4 mL of 0.1 M acetate buffer (pH 5.5) to which each sample (final concentration is listed in Table 3) was added with 0.4 mL of absolute ethanol and 0.5 mM DPPH absolute ethanol solution. .2 mL was added to prepare a reaction solution. In addition, in the case of an oil-soluble sample, the sample was added to 0.4 mL of absolute ethanol to prepare a reaction solution. Thereafter, the mixture was reacted at 37° C. for 30 minutes, and the absorbance (A) at 517 nm was measured using water as a control. Furthermore, as a control, absorbance (B) was measured using purified water instead of the sample. The DPPH radical scavenging rate was calculated using the formula shown below.
DPPH radical scavenging rate (%) = (1-A/B) x 100

これらの試験結果を表3に示した。本発明のオオヨモギの抽出物は、ヨモギの抽出物よりも顕著に優れたDPPHラジカル消去効果を有していることが認められた。 The results of these tests are shown in Table 3. It was found that the extract of Artemisia annua of the present invention has a significantly superior DPPH radical scavenging effect than the extract of Artemisia annua.

以上のことから、本発明のオオヨモギの抽出物は、優れたメラニン生成抑制効果、コラーゲン産生促進効果及び抗酸化効果を有しているので、本発明のオオヨモギの抽出物は、美容分野だけでなく、医療分野にも利用でき、食品、化粧品、医薬部外品及び医薬品等への応用が期待される。 From the above, the extract of Mugwort of the present invention has excellent melanin production inhibiting effects, collagen production promoting effects, and antioxidant effects, and therefore the extract of Mugwort of the present invention is useful not only in the beauty field. It can also be used in the medical field, and is expected to be applied to foods, cosmetics, quasi-drugs, pharmaceuticals, etc.

Claims (2)

オオヨモギ(Artemisia montana)のエタノール抽出物を0.001~10重量%含有することを特徴とするメラニン生成抑制剤。 A melanin production inhibitor characterized by containing 0.001 to 10% by weight of an ethanol extract of Artemisia montana. オオヨモギ(Artemisia montana)のエタノール抽出物を0.001~10重量%含有することを特徴とする、メラニンによる色素沈着の改善及び予防用食品組成物。 A food composition for improving and preventing pigmentation due to melanin, which contains 0.001 to 10% by weight of an ethanol extract of Artemisia montana.
JP2019218943A 2019-12-03 2019-12-03 Melanin production inhibitor, collagen production promoter and antioxidant Active JP7389465B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019218943A JP7389465B2 (en) 2019-12-03 2019-12-03 Melanin production inhibitor, collagen production promoter and antioxidant

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2019218943A JP7389465B2 (en) 2019-12-03 2019-12-03 Melanin production inhibitor, collagen production promoter and antioxidant

Publications (2)

Publication Number Publication Date
JP2021088519A JP2021088519A (en) 2021-06-10
JP7389465B2 true JP7389465B2 (en) 2023-11-30

Family

ID=76219444

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019218943A Active JP7389465B2 (en) 2019-12-03 2019-12-03 Melanin production inhibitor, collagen production promoter and antioxidant

Country Status (1)

Country Link
JP (1) JP7389465B2 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001206835A (en) 2000-01-25 2001-07-31 Kanebo Ltd Collagen synthesis promoter and collagen metabolism activator
JP2001114634A5 (en) 1999-10-12 2004-11-11
JP2005110760A (en) 2003-10-03 2005-04-28 Mitsubishi Electric Corp Antioxidant discharging device and antioxidant discharging method
JP2006104118A (en) 2004-10-04 2006-04-20 National Institute Of Advanced Industrial & Technology Bleaching effect-improving agent, method for producing the same, bleaching composition using the same and skin care preparation for external use containing the same
JP2016006021A (en) 2014-06-20 2016-01-14 株式会社ノエビア Thioredoxin-related factor expression promoter
CN109316416A (en) 2018-09-06 2019-02-12 广州华玺生物科技有限公司 A kind of Folium Artemisiae Argyi extract and its application in cosmetics

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0641419B2 (en) * 1986-03-19 1994-06-01 日清飼料株式会社 Ayu gill medicine
JPH07126149A (en) * 1993-10-28 1995-05-16 Suntory Ltd Cosmetic composition for beautifying and whitening
JPH11322569A (en) * 1998-05-12 1999-11-24 Lion Corp Composition for external use for skin
JP2001114634A (en) * 1999-10-12 2001-04-24 Pola Chem Ind Inc Catalase protecting agent and antiager cosmetic including the same
KR20140109221A (en) * 2013-03-05 2014-09-15 호서대학교 산학협력단 Cosmetic composition for skin cell regeneration and the use there of containing essential oil of Artemisia montana Pampan
KR102059513B1 (en) * 2017-09-01 2019-12-26 (주)뷰티화장품 Cosmetic composition for skin antioxidant or improving skin wrinkle comprising extracts of artemisiae argyi folium and cordyceps militaris

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001114634A5 (en) 1999-10-12 2004-11-11
JP2001206835A (en) 2000-01-25 2001-07-31 Kanebo Ltd Collagen synthesis promoter and collagen metabolism activator
JP2005110760A (en) 2003-10-03 2005-04-28 Mitsubishi Electric Corp Antioxidant discharging device and antioxidant discharging method
JP2006104118A (en) 2004-10-04 2006-04-20 National Institute Of Advanced Industrial & Technology Bleaching effect-improving agent, method for producing the same, bleaching composition using the same and skin care preparation for external use containing the same
JP2016006021A (en) 2014-06-20 2016-01-14 株式会社ノエビア Thioredoxin-related factor expression promoter
CN109316416A (en) 2018-09-06 2019-02-12 广州华玺生物科技有限公司 A kind of Folium Artemisiae Argyi extract and its application in cosmetics

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
第十七改正日本薬局方(平成28年3月7日厚生労働省告示第64号) 通則~医薬品各条(生薬等),「日本薬局方」ホームページ,2016年,第1758頁,https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000066530.html

Also Published As

Publication number Publication date
JP2021088519A (en) 2021-06-10

Similar Documents

Publication Publication Date Title
JP2021502953A (en) Cosmetic composition for skin whitening and wrinkle improvement containing Centella asiatica extract as an active ingredient
JP6437342B2 (en) A skin external preparation or an internal preparation containing an extract of echinacea cultivated by irradiating light having a specific wavelength range.
JP5512067B2 (en) Skin cosmetics
JP6803110B2 (en) External and internal skin preparations containing an extract of nasturtium cultivated by irradiating light with a specific wavelength range
JP6595192B2 (en) A skin external preparation or an internal preparation containing an extract of fenugreek cultivated by irradiation with light having a specific wavelength range.
JP5144362B2 (en) Topical skin preparation
JP7389465B2 (en) Melanin production inhibitor, collagen production promoter and antioxidant
JP7148115B2 (en) Collagen production promoter, MMP inhibitor, melanogenesis inhibitor, cell proliferation promoter, antioxidant, wrinkle improving agent, pharmaceutical or food composition
JP6731241B2 (en) Skin external and internal preparations using herb sprout
JP2008255043A (en) Skincare preparation for external use
JP6586691B2 (en) Skin external preparation or internal preparation containing an extract of chervil grown by irradiating light having a specific wavelength range
JP2008291001A (en) Skin cosmetic and food/drink for beauty use
JP5689552B1 (en) A skin external preparation or an internal preparation containing an extract of chamomile grown by irradiating light having a specific wavelength range.
JP7433628B2 (en) Skin external preparations and internal preparations
JP6281761B2 (en) External preparation or internal preparation containing Hidakami Sebaya extract
JP5690149B2 (en) External preparation or internal preparation
JP5415216B2 (en) Topical skin preparation
JP7539127B2 (en) Cell proliferation promoters, MMP-2 inhibitors, skin preparations for external use, medicines and internal preparations
JP5468866B2 (en) Topical skin preparation
JP5600421B2 (en) Skin preparation
JP2017088538A (en) Filaggrin production promoter
JP6646534B2 (en) Basic fibroblast growth factor production promoter
JP5690150B2 (en) External preparation or internal preparation
JP2024041161A (en) External preparation and internal preparation for skin
JP2022191664A (en) Collagen production promoter, mmp-2 inhibitor, cell growth promoter and internal agent

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221031

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231027

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231110

R150 Certificate of patent or registration of utility model

Ref document number: 7389465

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150